Advertisement

Tumor Biology

, Volume 33, Issue 3, pp 877–884 | Cite as

Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients

  • Dianke Yu
  • Juan Shi
  • Tong Sun
  • Xiaoli Du
  • Li Liu
  • Xiaojiao Zhang
  • Chao Lu
  • Xiaohu Tang
  • Meng Li
  • Lingchen Xiao
  • Zhouwei Zhang
  • Qipeng Yuan
  • Ming Yang
Research Article

Abstract

The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients. We systematically evaluate whether ERCC1 Asn118Asn and C8092A genetic variants are associated with treatment response of platinum chemotherapy. We preformed a meta-analysis using ten eligible cohort studies (including 11 datasets) with a total of 1,252 NSCLC patients to summarize the existing data on the association between the ERCC1 Asn118Asn and C8092A polymorphisms and response to platinum regiments. Odds ratio or hazard ratio with 95% confidence interval were calculated to estimate the correlation. We found that neither ERCC1 C8092A polymorphism nor Asn118Asn variant is associated with different response of platinum-based treatment among advanced NSCLC patients. Additionally, these two genetic variants are not related to treatment response in either Caucasian patients or Asian patients. Our meta-analysis indicates that the ERCC1 Asn118Asn and C8092A polymorphisms may not be good prognostic biomarkers for platinum-based chemotherapy in patients with stage III–IV NSCLC.

Keywords

Chemotherapy ERCC1 Meta-analysis Pharmacogenetics Platinum 

Notes

Acknowledgments

This work was supported by Beijing Nova Program (no. 2010B013 to M. Yang), the Fundamental Research Funds for the Central Universities (no. ZZ1234 to M. Yang) and National Natural Science Foundation of China (no. 30872968).

Conflicts of interest

None

Supplementary material

13277_2011_314_MOESM1_ESM.pdf (30 kb)
ESM 1 Treatment characteristics and genotyping methods of studies included in the meta-analysis (PDF 30 kb)

References

  1. 1.
    Gandara D, Narayan S, Lara Jr PN, Goldberg Z, Davies A, Lau DH, et al. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005;11(13 Pt 2):5057s–62s.PubMedCrossRefGoogle Scholar
  2. 2.
    Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350(4):379–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1(1):22–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–74.PubMedCrossRefGoogle Scholar
  5. 5.
    Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24(5):331–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307–20.PubMedCrossRefGoogle Scholar
  7. 7.
    de Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem. 1998;273(14):7835–42.PubMedCrossRefGoogle Scholar
  8. 8.
    Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996;86(5):811–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 2004;14(6):959–70.PubMedGoogle Scholar
  10. 10.
    Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res. 2002;8(7):2286–91.PubMedGoogle Scholar
  11. 11.
    Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16(1):309–16.PubMedGoogle Scholar
  12. 12.
    Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1and ERCC1in lung cancer. N Engl J Med. 2007;356(8):800–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol. 2004;15(8):1194–203.PubMedCrossRefGoogle Scholar
  15. 15.
    Yuan P, Miao XP, Zhang XM, Wang ZH, Tan W, Zhang XR, et al. Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy. Ai Zheng. 2005;24(12):1510–3.PubMedGoogle Scholar
  16. 16.
    Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, Yu LK, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28(1):315–21.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health. 2010;213(2):140–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol. 2010;33(5):489–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Kimcurran V, Zhou C, Schmid-Bindert G, Shengxiang R, Zhou S, Zhang L, et al. Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv Med Sci. 2011;56:30–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10(2):118–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56(2):281–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Wang J, Zhang Q, Zhang H, Wang Q, Yang X, Gu Y, et al. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Zhongguo Fei Ai Za Zhi. 2010;13(4):337–41.PubMedGoogle Scholar
  23. 23.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, et al. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol. 2010;40(10):954–60.PubMedCrossRefGoogle Scholar
  24. 24.
    Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797–803.PubMedCrossRefGoogle Scholar
  25. 25.
    HuGE Literature Finder. Available at URL: http://hugenavigator.net/HuGENavigator/startPagePubLit.do.
  26. 26.
    US National Library of Medicine, National Institutes of Health. PubMed home page. Available at URL: http://preview.ncbi.nlm.nih.gov/pubmed.
  27. 27.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMedGoogle Scholar
  28. 28.
    Petitti DB. Of babies and bathwater. Am J Epidemiol. 1994;140(9):779–82.PubMedGoogle Scholar
  29. 29.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCrossRefGoogle Scholar
  30. 30.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 2008;14(9):2878–86.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Dianke Yu
    • 1
  • Juan Shi
    • 2
  • Tong Sun
    • 3
  • Xiaoli Du
    • 4
  • Li Liu
    • 2
  • Xiaojiao Zhang
    • 2
  • Chao Lu
    • 2
  • Xiaohu Tang
    • 2
  • Meng Li
    • 2
  • Lingchen Xiao
    • 2
  • Zhouwei Zhang
    • 2
  • Qipeng Yuan
    • 2
    • 5
  • Ming Yang
    • 2
    • 5
  1. 1.State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.College of Life Science and TechnologyBeijing University of Chemical TechnologyBeijingChina
  3. 3.Department of Medical OncologyDana-Farber Cancer Institute and Harvard Medical SchoolBostonUSA
  4. 4.Laboratory of Cellular Oncology, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  5. 5.College of Life Science and TechnologyBeijing University of Chemical TechnologyBeijingChina

Personalised recommendations